BRK-B Research Update — June 20, 2026
Updated Thesis
Berkshire Hathaway Inc. is a diversified conglomerate primarily operating in financial services and insurance, with significant businesses in manufacturing, railroads, utilities, and retail. The company benefits from a structural moat driven by capital strength, reputation, and tax advantages rather than conventional product market share.
The investment grade as of this refresh is D — solid business quality. High-tier business, expensive valuation with 19.3% downside to $395.18 fair value
Key Metrics at a Glance
- Revenue growth: +4.4% year over year
- Net margin: 19.3%
- Forward P/E: 14.6x
- Fair value upside: -19.3% to our estimate of $395
Current price: $489.46
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Berkshire Hathaway Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full BRK-B research →](/stocks/BRK-B)